When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Acorda Therapeutics (ACOR) is in an unfavorable position with its (now former) main product Ampyra now a generic, the main existing asset Inbrija just entering the market and the company expected to burn a significant amount of cash in the following quarters. To further complicate matters and make the situation even harder, Acorda needs to address the elephant in the room – the $345 million convertible notes due in June 2021. The conversion price is far above the current share price and the notes are highly unlikely to be settled in shares and